UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models

Molecular cancer therapeutics, 2020-05, Vol.19 (5), p.1091-1101

2020

Volltextzugriff (PDF)

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Journal of medicinal chemistry, 2013-07, Vol.56 (14), p.5979-5983

2013

Volltextzugriff (PDF)

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Proceedings of the National Academy of Sciences - PNAS, 2013-09, Vol.110 (36), p.E3445-E3454

2013

Volltextzugriff (PDF)

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8), p.2587-2597

2013

Volltextzugriff (PDF)

Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814

Molecular cancer research, 2019-12, Vol.17 (12), p.2457-2468

2019

Volltextzugriff (PDF)

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2 -amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

The lancet oncology, 2012-11, Vol.13 (11), p.1133-1140

2012

Volltextzugriff (PDF)

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies

Molecular cancer therapeutics, 2022-06, Vol.21 (6), p.859-870

2022

Volltextzugriff (PDF)

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Proceedings of the National Academy of Sciences - PNAS, 2012-07, Vol.109 (29), p.11788-11793

2012

Volltextzugriff (PDF)

Cell Cycle Synchronization at the G2/M Phase Border by Reversible Inhibition of CDK1

Cell cycle (Georgetown, Tex.), 2006-11, Vol.5 (22), p.2555-2556

Vassilev, Lyubomir T

2006

Volltextzugriff (PDF)

Selective Small-Molecule Inhibitor Reveals Critical Mitotic Functions of Human CDK1

Proceedings of the National Academy of Sciences - PNAS, 2006-07, Vol.103 (28), p.10660-10665

2006

Volltextzugriff (PDF)

p53 Activation by Small Molecules: Application in Oncology

Journal of medicinal chemistry, 2005-07, Vol.48 (14), p.4491-4499

Vassilev, Lyubomir T

2005

Volltextzugriff (PDF)

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia

Scientific reports, 2021-06, Vol.11 (1), p.12148-14, Article 12148

2021

Volltextzugriff (PDF)

In vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Science (American Association for the Advancement of Science), 2004-02, Vol.303 (5659), p.844-848

2004

Volltextzugriff (PDF)

Small-Molecule MDM2 Antagonists Reveal Aberrant P53 Signaling in Cancer: Implications for Therapy

Proceedings of the National Academy of Sciences - PNAS, 2006-02, Vol.103 (6), p.1888-1893

2006

Volltextzugriff (PDF)

MDM2 inhibitors for cancer therapy

Trends in molecular medicine, 2007-01, Vol.13 (1), p.23-31

Vassilev, Lyubomir T

2007

Volltextzugriff (PDF)

Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells

Cell reports (Cambridge), 2016-03, Vol.14 (8), p.1858-1866

2016

Volltextzugriff (PDF)

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

Blood, 2005-11, Vol.106 (9), p.3150-3159

2005

Volltextzugriff (PDF)

DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia

Frontiers in oncology, 2020-02, Vol.10, p.127

2020

Volltextzugriff (PDF)

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5

Blood, 2008-04, Vol.111 (7), p.3742-3750

2008

Volltextzugriff (PDF)

Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin

Cancer research (Chicago, Ill.), 2007-08, Vol.67 (15), p.7350-7357

2007

Volltextzugriff (PDF)

Pharmacologic p53 Activation Blocks Cell Cycle Progression but Fails to Induce Senescence in Epithelial Cancer Cells

Molecular cancer research, 2009-09, Vol.7 (9), p.1497-1509

2009

Volltextzugriff (PDF)

Constitutive autophagy contributes to resistance to TP53-mediated apoptosis in Epstein-Barr virus-positive latency III B-cell lymphoproliferations

Autophagy, 2015-12, Vol.11 (12), p.2275-2287

2015

Volltextzugriff (PDF)

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

Cancer research (Chicago, Ill.), 2005-03, Vol.65 (5), p.1918-1924

2005

Volltextzugriff (PDF)

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines

BMC cancer, 2011-05, Vol.11 (1), p.211:1-211, Article 211

2011

Volltextzugriff (PDF)

Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML

Blood, 2010-01, Vol.115 (2), p.306-314

2010

Volltextzugriff (PDF)

1 – 25 von 137

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(131)
Mit Volltextzugriff
(120)

Publikationsform

Artikel
(136)
Buchkapitel
(1)

Sprache

Englisch
(137)

Erscheinungsjahr

n.n

Thema

Science & Technology
(88)
Life Sciences & Biomedicine
(80)
Humans
(66)
Animals
(43)
Tumor Suppressor Protein P53 - Metabolism
(33)
Biochemistry & Molecular Biology
(31)
Biological And Medical Sciences
(31)
Cell Line, Tumor
(31)
Mice
(28)
Proto-Oncogene Proteins C-Mdm2 - Antagonists & Inhibitors
(23)
Apoptosis
(22)
Apoptosis - Drug Effects
(21)
Imidazoles - Pharmacology
(20)
Proto-Oncogene Proteins C-Mdm2 - Metabolism
(20)
Medical Sciences
(19)
Piperazines - Pharmacology
(19)
Oncology
(18)
Female
(17)
Antineoplastic Agents - Pharmacology
(16)
Cancer
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2 -amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Cell Cycle Synchronization at the G2/M Phase Border by Reversible Inhibition of CDK1

Selective Small-Molecule Inhibitor Reveals Critical Mitotic Functions of Human CDK1

p53 Activation by Small Molecules: Application in Oncology

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia

In vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Small-Molecule MDM2 Antagonists Reveal Aberrant P53 Signaling in Cancer: Implications for Therapy

MDM2 inhibitors for cancer therapy

Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5

Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin

Pharmacologic p53 Activation Blocks Cell Cycle Progression but Fails to Induce Senescence in Epithelial Cancer Cells

Constitutive autophagy contributes to resistance to TP53-mediated apoptosis in Epstein-Barr virus-positive latency III B-cell lymphoproliferations

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines

Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML

Suchergebnisse filtern